Ipca Laboratories Limited · NSE:IPCALAB
Ipca Laboratories — Investor Presentation (December 2025)
65 slides from Ipca Laboratories's investor presentation, December 2025
Slide 1: Corporate Presentation December 2025
£ipca A dose of life Ipca Laborate Corporate Presentation December 2025
Slide 2: About Us
About Us a OOCOE Incorporation “Consolidated: income Export to >16, 000 | 70+ | FY202425 = = 100+ Employees . Wana can J years R89, 032 cs | countries with | | sites | labs USS1, 067 wn wanes | | |
Slide 3: Our Values
Our Values a wae Qualiti Safeti Integriti | Digniti _— Responsibilit’ Adhere to Ensure safety Comply with Value Facilitate good standards comes first : ethics & standards; people : business practices
Slide 4: Five Years' Highlights (Standalone)
Five Years’ Highlights XN %6,749.21 %6,277.75 ($797.50) 5,925.81 ($757.82) ($738.69) %5,491.22 5,201.40 ($737.38) ($699.20) Sean %3,570.05 465.59 3,282.39 A 2,983.09 ($409.17) ee) siete ($400.58) 333.94 oO -O- ~2 22,717. 2,508.13 % 2,643.42 %2,707.70 2,808.96 Geog (5336.80) (5329.52) (5326.86) ($331
Slide 5: Five Years' Highlights (Consolidated)
Five Years’ Highlights Consolidated %9,032.39 10000 ($1,067.28) 9000 27,829.81 ($945.17) 8000 £5 96.36 6,369.94 7000 5,482.83 aan ($794.06) 6000 ($737.03) eagoa.t6 5000 a ($578.30) 3,391.06 ($451.47) 2,818.61 , 4000 | 2,519.77 Gare ($422.72) 24,138.23 %4089.87 ($488.98) (5338.72) 3000 e—6 2000 2,963
Slide 6: Slide 6
Slide 7: Manufacturing Sites: Formulations
B® Formulations @® rep B® Biotech WD Corporate Office IpcaLaboratories *Unichem Overseas Pisgah Labs (Pisgah, NC) Indore Cluster Pithampur(SEZ). . SilvassaCluster & Kandla wiacum Mumbai Cluster Manufacturing Sites & Badd (2 facilities) & Dehradun (2 facilities) Ratam Formulations Ghaziabad & Joretha
Slide 8: Manufacturing Sites: Formulations
Athal (Dadra & Nagar Haveli) Ratlam (Madhya Pradesh) Kandla (Gujarat) Silvassa (Dadra & Nagar Haveli) Dehradun (Uttarakhand) Indore (SEZ) (Madhya Pradesh) Sikkim Tablets & Capsules Tablets, Liquids, Dry Syrup, Injectables & Ointments Betalactum-Tablets, Capsules & Dry Syrups Tablets & Capsules Table
Slide 9: Manufacturing Sites: Active Pharmaceutical Ingredients
Manufacturing Sites < Active ‘ naceutical Ingredients age : “
Slide 10: Manufacturing Sites: APIs
rom) Onyx Scientific (Sunderland) WD Apis and / or intermediates @ rao B® Biotech WD Corporate Office Pisgah Labs (Pisgah, NC) IpcaLaboratories *Unichem Laboratories * Krebs Biochemicals Indore Cluster Hingni ° , Baroda Cluster Mumbai Cluster Mumbai.. Mum! Manufacturing Sites APIs > Chh, Sambhajinag
Slide 11: Manufacturing Sites: APIs
Manufacturing Sites APIs [ Location | Inspections / Approvals by Agencies of ] e@ Ratlam (Madhya Pradesh) Australia, Brazil, Canada, EDQM, EU, India, Japan, Korea, Mexico, Russia, Slovenia, USA, WHO © Indore Madhya Pradesh) nig B,WHO @ Dewas (Madhya Pradesh) EU, India, Russia © Nandesari Gujrat) Ind
Slide 12: Revenue Break-up
Reven ue Break- -up
Slide 13: Revenue Break-up
Revenue Break-up Standalone 2024-25 Total Total Revenue Exports Domestic 2024-25 2024-25 2024-25 2024-25 e e e e Formulations: APIs Formulations e APIs Formulations : Export Domestic : APIs @ Formulations @ APIs @ Domestic @ Exports @ Formulations @® APIs @ Formulations @® APIs
Slide 14: Revenue Break-up
Revenue Break-up Standalone 2024-25 2023-24 Crs | Domestic | Exports | Total | Domestic | Exports | Total Growth | @ Branded Formulations 3,450.21 581.89 4,032.10 3,097.16 526.70 3,623.86 1 Tar ome 489 | 1336.69 | 1,341.58 . 1,248.62 1,248.62 © Total Formulations 3,455.10 1,918.58 5,373.68 3,097.16
Slide 15: Financials FY 2023-24 & FY 2024-25
Slide 16: FY 2024-25 vs FY 2023-24
FY 2024-25 FY 2023-24 Zs US$ Mn || Zs US$ Mn | % Growth Total Income 6,749.21 797 6,277.75 758 8% e EBIDT 1,513.33 179 1,189.54 144 e@ EBIDT% 22.66% - 19.29% - fF e PBT* 1,281.31 151 955.52 115 @ PBT% 19.19% - 15.50% - fF @ PAT 650.76 77 530.41 64 16 # After forex gain of £11.70 Crs as against £21.8
Slide 17: Financials: Profitability
Financials Standalone CO Profitability | FY 2024-25 FY 2023-24 PBIDT 22.66% @ point WB Pst WB PAT @ point WB Pst WB PAT
Slide 18: Business Characteristics
Business Characteristics Return on Capital Employed % (PBIT / Capital Employed) Return on Net Worth % (PAT / Net Worth) Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) Capital Employed Turnover Ratio (Total Income / Capital Employed) Asset Coverage Ratio (to term loan) (Net Fixed Assets
Slide 19: Financials: Net Profit
Financials Standalone FY 2024-25 FY 2023-24 @ Net Profit 22.7% 4.9%
Slide 20: Standalone Q1 FY26
Standalone Q1 FY26 Q1 FY25 ZCrs US$ Mn | | ZCrs US$ Mn | % Growth © Total Income 1,771.92 207 1,581.25 — © EBIDT 416.04 49 348.44 e@ EBIDT% 23.82% - 22.25% @ PBT* 356.75 42 287.89 @ PBT% 20.42% - 18.39% @ PAT* 262.04 31 204.13 @ PAT% 15.00% - 13.04% # After forex loss of £9.12 Crs as against forex g
Slide 21: Standalone Q2 FY26
Standalone Q2 FY26 Q2 FY25 ZCrs US$ Mn | | ZCrs US$ Mn | % Growth @ Total Income 1,952.24 223 1,827.94 — e EBIDT 491.47 56 414.47 e@ EBIDT% 25.46% - 22.89% @ PBT* 408.31 47 339.21 e@ PBT% 21.15% - 18.73% @ PAT* 304.74 35 244.12 @ PAT% 15.79% - 13.48% # After forex loss of $26.76 Crs as against of €1
Slide 22: Standalone Q3 FY26
Standalone Q3 FY26 Q3 FY25 ZCrs US$ Mn | | ZCrs US$ Mn | % Growth @ Total Income 1,863.00 209 1,680.09 — e EBIDT 481.42 54 403.27 e EBIDT% 26.09% - 24.25% @ PBT* 417.22 47 355.52 e@ PBT% 22.61% - 21.38% @ PAT* 303.45 34 267.56 @ PAT% 16.45% - 16.09% # After forex loss of $3.94 Crs as against forex g
Slide 23: Standalone Nine Months FY26
Standalone 9 Mths FY26 9 Mths FY25 ZCrs US$ Mn | | ZCrs US$ Mn | % Growth @ Total Income 5,587.16 639 5,089.28 — e EBIDT 1,388.93 159 1,166.18 e@ EBIDT% 25.15% - 23.14% @ PBT* 1,182.28 135 982.62 e@ PBT% 21.41% - 19.50% @ PAT* 870.23 100 715.81 @ PAT% 15.76% - 14.20% # After forex loss of $39.82 Crs
Slide 24: Financials: Consolidated
Financials Consolidated FY 2024-25 FY 2023-24 ZCrs US$ Mn | f ZCrs US$ Mn © Total Income 9,032.39 1,067 7,829.81 e EBIDT 1,693.13 200 1,288.21 e@ EBIDT% 18.94% - 16.72% @ PBT* 1,336.19 158 842.67 @ PBT% 14.95% - 10.94% @ PAT* 737.68 87 547.35 @ PAT% 8.25% - 7.10% # After forex gain of £33.01 Crs.as
Slide 25: Financials: Consolidated Business Characteristics
Financials Consolidated Business Characteristics FY 2024-25 FY 2023-24 Return on Capital Employed % (PBIT / Capital Employed) 19.88% 16.30% Return on Net Worth % (PAT / Net Worth) 14.09% 11.47% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.45 2.12 Capital Employed Turnover Ratio (To
Slide 26: Financials: Consolidated Net Profit
Financials Consolidated FY 2024-25 FY 2023-24 © Net Profit 34.8% 9.2%
Slide 27: Consolidated Q1 FY26
Financials Consolidated Q1 FY26 Q1FY25 Crs US$ Mn Crs US$ Mn © Total Income 2341.51 274 2,113.24 @ EBIDT 424.58 50 387.49 e@ EBIDT % 18.39% = 18.52% @ PBT* 330.51 39 290.39 @ PBT% 14.31% > 13.88% @ PAT* 233.21 27 192.24 @ PAT% 10.10% > 9.19% # After forex loss of $8.16 Crs as against forex gain of €
Slide 28: Consolidated Q2 FY26
Q2 FY26 Q2 FY25 ZCrs US$ Mn | f ZCrs US$ Mn % Growth © Total Income 2,584.36 296 2,381.16 e EBIDT 554.31 63 449.83 e@ EBIDT% 21.68% - 19.10% @ PBT* 449.84 51 344.83 @ PBT% 17.60% - 14.64% @ PAT* 282.57 32 229.48 @ PAT% 11.05% - 9.74% # After forex loss of £9.39 Crs as against €8.35 Crs for previous
Slide 29: Consolidated Q3 FY26
Financials Consolidated Q3 FY26 Q3 FY25 Crs US$ Mn Crs US$ Mn © Total Income 2,412.69 270 2,265.48 @ EBIDT 529.86 59 446.07 e@ EBIDT % 22.15% = 19.87% @ PBT* 428.33 48 367.92 @ PBT% 17.90% > 16.39% @ PAT* 326.27 37 248.14 @ PAT% 13.64% > 11.05% # After forex gain of £3.49 Crs as against €17.01 Crs f
Slide 30: Consolidated Nine Months FY26
9 Mths FY26 9 Mths FY25 ZCrs US$ Mn | f ZCrs US$ Mn % Growth © Total Income 7,338.56 839 6,759.88 e EBIDT 1,508.75 173 1,283.39 e@ EBIDT% 20.79% - 19.18% @ PBT* 1,208.68 138 1,003.14 @ PBT% 16.65% - 14.99% @ PAT* 842.05 96 669.86 @ PAT% 11.60% - 10.01% # After forex loss of $14.06 Crs as against for
Slide 31: Contribution of Therapeutic Groups
2024-25 Domestic 2023-24 © Cardiovasculars& Anti-Diabetics © AntiMalarials © Neuro Psychiatry e 3% 3% © Cough Preparations Ba © Dermatology e 6% 6% © Urn Ba © ‘Neutraceuticas e % 1% ets aw ec Financials Standalone Contribution of Therapeutic Groups a Therapeutic Segment — Export 2024-25 2023-24 © Ca
Slide 32: Branded Formulations
Branded| Formulations
Slide 33: Branded Formulations: Domestic
Branded Formulations a Domestic . 22 Market leaders in All India Rank IQVIA Therapy Focused Over 4000 Rheumatoid Arthritis 16" (MAT Dec’25) Marketing Divisions Wholesalers & Anti-malarials Gy @ 24 Depots & Field Strength 6 brands among ‘1 C&F agent (PSR /BA)-7245 top 300 brands (Zerodol-SP, Zerodol-
Slide 34: Branded Formulations: Domestic Sales
Branded Formulations Domestic (soo 3,455.10 > %3,097.16 ($408.26Mn) ($374 Mn) %2,760.71 2,508.27 ($344Mn) ($337 Mn) —O— 202425 0 T T T 1 2021-22 \ 2021-22 2022-23 2023-24 2024-25 2022-23 SD) 2023-24 Figures in Crores. Sales
Slide 35: Domestic Future Growth Drivers
Branded Formulations Domestic Future Growth Clinical research as a tool to launch innovative combination Drivers formulations / NDDS rail [—® Strong brand building with focused promotion -—e In-licensing / out-licensing to build business in the promoted therapy Portfolio optimisation, strategies to
Slide 36: International
\ Intern ational
Slide 37: International Business
International Business a Registrations in 61 countries © Recognised _A Field-force to promote brands © Five Star Export gu in more than House 30 countries Products of the company 42% sales & Marketing offices in are now exported to over From exports By 12 countries 100 countries across the globe
Slide 38: International Business Sales
International Business (— > %2,808.96 3000 50993 %2,643.42 70770 ($332 Mn) ($337 Mn) ($330 Mn) 2500 2000 1500 1000 500 —O- 2024.25 9 ' u T 1 2021-22 LL 2021-22 2022-23 2023-24 2024-25 y “4 Figures in Crores. Sales 38
Slide 39: Continent-wise Exports 2024-25
International Business a Continent-wise Exports 2024-25 (%Crs) Continent Formulations APIs | Total | % Contribution © Europe 525.00 281.11 806.11 29% © Africa 502.30 43.40 545.70 19% © Americas 267.43 268.57 536.00 19% @ Asia 137.22 254.64 391.86 14% e dls 210.42 35.84 246.26 9% © Australasia 276.21
Slide 40: International Formulations
Slide 41: International Formulations Sales
International Formulations 21,918.58 21,775.32 ($227 Mn) 21,639.19 ($214Mn) ($204 Mn) 1,486.74 ($200 Mn) XX 2021-22 2022-23 2023-24 2024-25 ~ w —O— 2024-25 2021-22 2022-23 2023-24 Figures in Crores. Sales 41
Slide 42: International
Intern ational
Slide 43: International Branded Formulations
International Branded Formulations (— 581.89 >) 590 ($69 Mn) 570 550 %526.70 530 504.79 ($64 Mn) 510 ($63 Mn) 490 470 450 415.99 430 ($56 Mn) 410 390 370 350 —O- 2024-25 330 T T T 1 2021-22 S 2021-22 2022-23 2023-24 2024-25 O- 022 Figures in Crores. Sales 4B
Slide 44: Branded Formulations Future Growth Drivers
International Branded Formulations Future Growth _ Thrust on brand building in Pain, CVS, CNS, Anti-infective Drivers and Anti-malarial segments ral —® Geographical expansion in covered countries through additional field force ‘—® Expansion in business lines - Institutions and Distributors Introduct
Slide 45: International: Generics / Institution / Tender
@ eo ae tional NS nstitution / Tender so Ane SS 5
Slide 46: International Generics / Institution / Tender
International Generics / Institution / Tender >) Products Products Under 00 1,248.62 ane | Country | Registered Registration | (5151 Mn) PITA United Kingdom 1200 )=1,070.75 _&1,134.40 ~ ; ($144Mn) (5141 Mn) / Europe 1000 Australia / 16 2 New Zealand 800 South Africa 53 10 60 United States / 50 6 400
Slide 47: International Generics Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries al Formulations registered to be backed by own API Sale of generic dossiers with or without supply agreements Contract manufacturing arrangements Future Gr
Slide 48: International: APIs
internat ational
Slide 49: International APIs Sales
International APIs ~ 1200 1.02139 $1,004.23 137 Mn ($125 Mn) E 932.38 %390.. 1000 ($113 Mn) (an iin) 800 600 400 200 —O- 2024.25 4 2021-22 2021-22 2022-23 2023-24 2024-25 701324 L ) 2023-24 Figures in Crores. Sales 49
Slide 50: APIs - Drug Master Files
International APIs - Drug Master Files AA DME | Name of the API US-FDA Canada- wHo | /Pa% | Australia| EQDM 1 1 Alendronate Sodium () cs - 7) - i} 2 2 Allopurinol (7) @ = = CEP @ 3 3 Amlodipine Besylate () = - - z 4 Amlodipine Besylate (AK4 Process) - - - = ° Gg 4 5 Amodiaquine HCI = S @ - - - 5 6 A
Slide 51: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 11 12 12 13 13 14 14 15 15 16 16 7 18 17 19 18 20 21 19 22 Name of the API Benzarone Benzbromarone Bisoprolol Fumarate Bupropion Hydrochloride Carvedilol Celecoxib Cetrizine Hydrochloride Cetrizine Hydrochloride (CZ5 / CZ6 Process) Chloroquine Phosphate Chlorthalidone (CT3
Slide 52: APIs - Drug Master Files
International APIs - Drug Master Files 31 Famotidine (FM3 Process) 2 2 - - . 27 32 Fenofibrate = 2 - - - 28 33 Fluconazole > 2 - - - API | DMF 7 Canada- Japan- Sr.No.|Sr.No.| Name of the API US-FDA HPEB WHO PMDA Australia EQDM 20 23 Citalopram HBR - = = o - @ 21 24 Dihydroartemesinin = S Gg - - - 22
Slide 53: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Dec’25 (Based on DMFs Sr. No.) API | DMF Canada- Japan- Sr. No.| Sr. No. Name of the API US-FDA HPEB WHO PMDA Australia EQDM | 0 35 Furosemide ° — : ° CEP sd 36 Furosemide (Veterinary) 38 _Felodipine a 40 Hydrochlorothiazide (Process |) 3
Slide 54: APIs - Drug Master Files
International APIs - Drug Master Files AA DME | Name of the API usFoa | Canada yg | JPan justralia | EQDM 37 45 Hydroxyzine Pamoate (7) - = 2 - - 38 46 Indapamide - = = o - @ 39 47 Lamotrigine - = = 2 - () rn 48 Losartan Potassium (LB4 Process) @ - 2 2 - (7) 49 Losartan Potassium (LB7 Process) = @ -
Slide 55: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Dec’25 (Based on DMFs Sr. No.) API | DMF 7 Canada- Japan- ca A F | Name ofthe API | US-FDA | Lu | WHO PMDA er EQDM | 56 Methylphenidate HCI ee 58 Metoclopramide HCI 59 Metoclopramide HCl (M Process) ee 61 Metoprolol Tartrate 62 Metoprolol
Slide 56: APIs - Drug Master Files
International APIs - Drug Master Files oA. OME | Name of the API usFoa | Canada yg | JPan justralia | EQDM 55. 67 Ondansetron Hydrochloride (7) @ - - CEP (7) 56 68 _ Paroxetine HCI : : : : CEP @ 57 69 Piperaquine Phosphate - - g@ - - - 58 70 _ Primaquine Phosphate i) = = = g@ g 59 71 Proguanil Hydro
Slide 57: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 65 78 66 79 80 67 81 82 68 83 69 84 70 85 71 86 72 87 23 88 Name of the API Risendronate Sodium Hemi-Pentahydarate Risperidone Telmisartan Telmisartan (WT6 Process) Telmisartan (WT3A Process) Torsemide Tramadol Hydrochloride (YT3 Process) Trazodone Hydrochloride Triamteren
Slide 58: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Dec’25 (Based on DMFs Sr. No.) API | DMF Canada- Japan- A | si AR F | Name ofthe AP | US-FDA | HPEB WHO PMDA | Australia| ‘. 89 Warfarin Sodium Clathrate a a
Slide 59: APIs Future Growth Drivers
International APIs -—® Consolidate API business of Sartans across the globe Future Growth Drivers —e Long term strategic tie-ups with major South American / European formulators Leverage the customer base of more than 1000 customers spread across 90 _A countries is well laid down platform to introdu
Slide 60: Research & Development
AS Resear rh& Development
Slide 61: Research & Development Spending
Research & Development APIs & Formulations ( ) Year | Xrs | wtosaes | 220 T207-08 5.50% 200 - 5.00% 2020-21 126.67 2.49% £161.50 180 %146.46 %156.49 2.64% ae 2021-22 141.46 2.63% 10 TS 2.63% 271% 4.00% 14g |< 26-67 3.50% 2022-23 156.49 271% 120 3.00% 100 _— 2023-24 161.50 2.64% th 2.00% 202425 207.0
Slide 62: Research & Development: APIs & Formulations
Research & Development APls & Formulations -—® Current scientist manpower of 650+ Research focus on developing APIs with non-infringing process and development of finished dosage forms Development of NDDS for domestic and international market 285 patent applications filed Biotech / fermentation rese
Slide 63: Overview of Advanced Biotech Lab
Overview of Advanced Biotech Lab Biosimilar R&D and Bio-manufacturing -—® Established “state-of-the-art” R&D in 2015 for Mammalian based mAbs Capable of in-house development from “Clone to Commercialisation” Single-use CGMP Bio-manufacturing Facility (DS+DP+QC) is being established and to be ready b
Slide 64: Strong Biosimilar Pipelines
Strong Biosimilar Pipelines Molecules: Anti-cancer , Anti-inflammatory and Ophthalmic mAbs Stage of Development [ Molecules e 7 Monoclonal antibodies (mAbs) and One Non- MAA/ Launch mAb Biosimilar at various stages of the development UK/CA/IN/EU © Target markets India, UK, CA, EU, ROW /USA followed
Slide 65: Thank You
Ipca Laboratories — Investor Presentation (December 2025) on 6ix